How many drugs treat Juvenile idiopathic arthritis?

Drug Landscape tracks 10 marketed treatments for Juvenile idiopathic arthritis (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/juvenile-idiopathic-arthritis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Juvenile idiopathic arthritis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Juvenile idiopathic arthritis (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Juvenile idiopathic arthritis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Roactemra	tocilizumab	Roche	Interleukin-6 Receptor Antagonist [EPC]	Interleukin-6 receptor	2010-01-01
Simponi	GOLIMUMAB	Centocor Ortho Biotech Inc	Tumor Necrosis Factor Blocker [EPC]	Tumor necrosis factor	2009-01-01
Orencia	abatacept	Bristol-Myers Squibb	Selective T cell costimulation modulator	CD80, CD86, CD28	2005-01-01
Humira	ADALIMUMAB	AbbVie	TNF blocker	Tumor Necrosis Factor-alpha (TNF-alpha)	2002-01-01
Abrilada	Adalimumab-Afzb	AbbVie	TNF blocker	Tumor necrosis factor-alpha (TNF-alpha)	2002-01-01
Enbrel	etanercept	Immunex	Tumor Necrosis Factor Blocker [EPC]	Tumor necrosis factor	1998-01-01
Trexall	methotrexate	Generic (originally Lederle Laboratories)	Antifolate, DMARD	Canalicular multispecific organic anion transporter 1, High mobility group protein B1, Multidrug resistance-associated protein 4	1953-12-07
Simponi	Simponi	Alvotech Swiss AG		Tumor necrosis factor
Humira	Humira	Sohag University		Tumor necrosis factor
tumor necrosis factor inhibitors (TNFi)	tumor-necrosis-factor-inhibitors-tnfi	Pfizer	biologic	tumor necrosis factor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Pfizer · 4 drugs in Juvenile idiopathic arthritis
Bristol-Myers Squibb · 2 drugs in Juvenile idiopathic arthritis
AbbVie · 2 drugs in Juvenile idiopathic arthritis
Biocad · 1 drug in Juvenile idiopathic arthritis
Centocor Ortho Biotech Inc · 1 drug in Juvenile idiopathic arthritis
Generic (originally Lederle Laboratories) · 1 drug in Juvenile idiopathic arthritis
Immunex · 1 drug in Juvenile idiopathic arthritis
LG Life Sciences · 1 drug in Juvenile idiopathic arthritis
Roche · 1 drug in Juvenile idiopathic arthritis
Sohag University · 1 drug in Juvenile idiopathic arthritis
Alvotech Swiss AG · 1 drug in Juvenile idiopathic arthritis
BOEHRINGER INGELHEIM · 1 drug in Juvenile idiopathic arthritis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Juvenile idiopathic arthritis:

Cite this brief

Drug Landscape (2026). Juvenile idiopathic arthritis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/juvenile-idiopathic-arthritis. Accessed 2026-06-10.

Juvenile idiopathic arthritis full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing